4//SEC Filing
IDENIX PHARMACEUTICALS INC 4
Accession 0001209191-14-050688
CIK 0001093649operating
Filed
Aug 4, 8:00 PM ET
Accepted
Aug 5, 5:43 PM ET
Size
15.5 KB
Accession
0001209191-14-050688
Insider Transaction Report
Form 4
WYZGA MICHAEL S
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−5,000→ 0 totalExercise: $11.93Exp: 2022-02-28→ Common Stock (5,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−20,000→ 0 totalExercise: $4.94Exp: 2023-06-05→ Common Stock (20,000 underlying) - Disposition to Issuer
Stockl Option (Right to Buy)
2014-08-05−20,000→ 0 totalExercise: $9.03Exp: 2022-06-06→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−20,000→ 0 totalExercise: $6.88Exp: 2024-06-04→ Common Stock (20,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2014-08-05−15,000→ 0 totalExercise: $11.93Exp: 2022-02-28→ Common Stock (15,000 underlying)
Footnotes (5)
- [F1]These options, which vested in 24 equal monthly installments beginning on April 1, 2012, were cancelled pursuant to the Agreement and Plan of Merger between the Issuer and Merck & Co. Inc. (the "Merger Agreement") in exchange for a cash payment of $12.57 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F2]These options, which vested in 3 equal monthly installments beginning on April 1, 2012, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $12.57 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F3]These options, which vested in 12 equal monthly installments beginning on July 7, 2012, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $15.47 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F4]These options, which vested in 12 equal monthly installments beginning on July 6, 2013, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $19.56 per share, representing the difference between the exercise price of the options and $24.50 per share.
- [F5]These options, which vested in 12 equal monthly installments beginning on July 5, 2014, were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $17.62 per share, representing the difference between the exercise price of the options and $24.50 per share.
Documents
Issuer
IDENIX PHARMACEUTICALS INC
CIK 0001093649
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001093649
Filing Metadata
- Form type
- 4
- Filed
- Aug 4, 8:00 PM ET
- Accepted
- Aug 5, 5:43 PM ET
- Size
- 15.5 KB